17 results
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
studies evaluating Frataxin and CTI-1601’s effects on a model of neurodegeneration June 12 – 15, 2022 XXIV World Congress International Society for Heart
DEFM14A
LRMR
Larimar Therapeutics Inc
29 Apr 20
Proxy related to merger
3:20pm
School at the University of Pennsylvania. He is a member of the Licensing Executives Society and is a Certified Public Accountant, Certified Management
PRER14A
LRMR
Larimar Therapeutics Inc
10 Apr 20
Preliminary revised proxy
4:38pm
of the Licensing Executives Society and is a Certified Public Accountant, Certified Management Accountant and a Certified Licensing Professional.
Related Person
PREM14A
LRMR
Larimar Therapeutics Inc
6 Mar 20
Preliminary proxy related to merger
5:32pm
of the Licensing Executives Society and is a Certified Public Accountant, Certified Management Accountant and a Certified Licensing Professional.
Related
8-K
EX-2.1
z58s13ytalrc3
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
DEFA14A
EX-2.1
p8u2n2grkzi9707c1
18 Dec 19
Additional proxy soliciting materials
8:11am
8-K
EX-99.1
va4og8u
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
10-K
wxjdum11kuolsl4chp0
25 Mar 15
Annual report
12:00am
424B4
myto 6fj9cj8pgug
23 Jan 15
Prospectus supplement with pricing info
12:00am
424B4
dfx 3shrl626vt
19 Jun 14
Prospectus supplement with pricing info
12:00am
S-1
m9ntn
18 Apr 14
IPO registration
12:00am
- Prev
- 1
- Next